PureTech Health plc (PTCHF)

Market Cap	445.16M
Revenue (ttm)	6.39M
Net Income (ttm)	50.68M
Shares Out	n/a
EPS (ttm)	0.20
PE Ratio	8.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	2,637
Open	1.900
Previous Close	1.900
Day's Range	1.900 - 1.900
52-Week Range	1.270 - 2.200
Beta	0.82
RSI	85.50
Earnings Date	Nov 28, 2025

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 56
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTCHF